What is Summit Therapeutics's free cash flow?

Summit Therapeutics (SMMT) reported free cash flow of -$122.54M in Q1 2026.

How has Summit Therapeutics's free cash flow changed year-over-year?

Summit Therapeutics's free cash flow decreased by 99.0% year-over-year, from -$61.59M to -$122.54M.

What is the long-term trend for Summit Therapeutics's free cash flow?

Over 3 years (2021 to 2025), Summit Therapeutics's free cash flow has grown at a 64.3% compound annual growth rate (CAGR), from -$72.89M to -$323.59M.

Summit Therapeutics SMMT Free cash flow

Free cash flow at other companies

Merck & Co.MRK

$2.93B+150%

Bristol-Myers SquibbBMY

$757M-55.3%

AbbVieABBV

$3.56B+155%

ExelixisEXEL

——

IncyteINCY

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Calculated from Summit Therapeutics’s reported figures.

−$122.3Mnet cash from operating−$245.0Kcapital expenditures=-$122.54M

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's free cash flow?: Summit Therapeutics (SMMT) reported free cash flow of -$122.54M in Q1 2026.
How has Summit Therapeutics's free cash flow changed year-over-year?: Summit Therapeutics's free cash flow decreased by 99.0% year-over-year, from -$61.59M to -$122.54M.
What is the long-term trend for Summit Therapeutics's free cash flow?: Over 3 years (2021 to 2025), Summit Therapeutics's free cash flow has grown at a 64.3% compound annual growth rate (CAGR), from -$72.89M to -$323.59M.